Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aptevo Therapeutics (APVO) Income from Continuing Operations (2016 - 2025)

Aptevo Therapeutics' Income from Continuing Operations history spans 11 years, with the latest figure at 7610000.0 for Q3 2025.

  • For Q3 2025, Income from Continuing Operations fell 45.98% year-over-year to 7610000.0; the TTM value through Sep 2025 reached 26698000.0, down 8.52%, while the annual FY2024 figure was 24602000.0, 31.91% down from the prior year.
  • Income from Continuing Operations for Q3 2025 was 7610000.0 at Aptevo Therapeutics, down from 6226000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 4040000.0 in Q4 2021 and bottomed at 8178000.0 in Q2 2023.
  • The 5-year median for Income from Continuing Operations is 6480000.0 (2025), against an average of 6517736.84.
  • The largest annual shift saw Income from Continuing Operations soared 40.75% in 2021 before it crashed 90.2% in 2022.
  • A 5-year view of Income from Continuing Operations shows it stood at 4040000.0 in 2021, then plummeted by 90.2% to 7684000.0 in 2022, then grew by 16.93% to 6383000.0 in 2023, then increased by 0.02% to 6382000.0 in 2024, then decreased by 19.24% to 7610000.0 in 2025.
  • Per Business Quant, the three most recent readings for APVO's Income from Continuing Operations are 7610000.0 (Q3 2025), 6226000.0 (Q2 2025), and 6480000.0 (Q1 2025).